The present invention includes fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing such fusion peptides, virosomes comprising such fusion peptides, and uses of such fusion peptides or virosomes for the prevention, treatment or amelioration of a cancer characterized by expression or over-expression of the Her2/neu …

Legal parties

Inventors (applicants): Mario Amacker, Andreas Kammer, Rinaldo Zurbriggen
Assignees (initial): Pevion Biotech AG (Ittigen, CH)
Agents: Kathryn Doyle (attorney), Saul Ewing, LLP (attorney)

The application was examined by Brad Duffy (USPTO dept. 1642), Nelson B Moseley, II


  • 1. A fusion peptide comprising three non-contiguous B cell epitopes from the extracellular domain (ECO) …
  • 2. The fusion peptide of claim 1 , wherein the amino acid sequence of the fusion …
  • 3. A method of preparing a fusion peptide of claim 1 : …

International priority data

EP: 09010627 / Aug. 18, 2009 (regional)

Cited documents


  • EP 1236740 A1, Feb. 1, 2001
  • EP 1844788 A1, Apr. 1, 2006
  • Kaumaya et al. US 7060284 B1, Jun. 1, 2006
  • Waelti US 2006/0275777 A1 / 435/6, Dec. 1, 2006
  • CN 1749276 A, Mar. 1, 2006


Brief Description of the Figures

FIG. 1 Representative demonstration that fusion peptides according to the invention induce higher antibody levels against a given B cell epitope than induced by a single peptide containing only …


Field of the Invention

The present invention relates to fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing such fusion peptides, virosomes comprising such fusion peptides, and uses of such fusion …

Detailed Description of the Invention

As described above, one aspect of the invention provides a fusion peptide comprising three non-contiguous B cell epitopes from the extracellular domain (ECD) of Her2/neu, or derivatives thereof, linked to one another …


The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials …

More details about Multiepitope Vaccine for Her2/Neu-associated Cancers

Miscellaneous patent data

The assignee is categorized as a foreign company or corporation, the application publication date is Aug. 18, 2010, the known applicant's name is Amacker Mario, the invention is titled Multiepitope Vaccine for Her2/Neu-associated Cancers, the patent is illustrated by 6 drawings, claims 1-15 comprise the invention scope, numbered 13/389,419 (application), invented by Rinaldo Zurbriggen et al., the exemplary patent drawings are Multiepitope Vaccine for Her2/Neu-associated Cancers, Demonstration that fusion peptides PEV606, Relative antibody responses to the individual, Sums of normalized OD ratios, the published agent's name is Doyle Kathryn, the invention details are shown in 6 figures, the patent particularly claims a fusion peptide comprising three non-contiguous B cell epitopes…, the assignee company is Pevion Biotech AG located in Ittigen (CH), the grant number is 08852604, originally classified under Fusion protein or fusion polypeptide, the inventor's name is Mario Amacker, similar classification categories are Antibody or Antigen-Binding Fragment Thereof That Binds Gram-Positive Bacteria, chromatography, attached to the carrier via a bridging agent, Nonionic surfactant containing, Motilins, Angiotensins, Related peptides, Hydrogen metal cyanide, cyanide, cyanate, or thio analog thereof, the first amino acid being heterocyclic, e.g. Pro, His, Trp, Marek's disease virus, from Nocardia, Carrier-bound or immobilised peptides, Preparation thereof, Aluminum, calcium or magnesium element, or compound containing, the side chain of the first amino acid being acyclic, e.g. Gly, Ala, Corrosion Inhibitor, Peptides having more than 20 amino acids, Gastrins, Somatostatins, Melanotropins, Derivatives thereof, the examination was conducted by Brad Duffy, the main examiner, Nelson B Moseley, II, the assistant (1642 USPTO department), the patent was granted on Oct. 7, 2014, the claim number 1 is selected as exemplary.

Invention classification information

The invention is classified under Hybrid peptides, for growth factors, for growth regulators, Medicinal preparations containing antigens or antibodies, Fusion protein or fusion polypeptide.

Patent details
Publication number 08852604
Publication date Oct. 7, 2014
Kind code B2
Application number 13/389,419
Application date Aug. 18, 2010
Application type U
Application series code 13
Int. pub. country WO
Int. pub. number WO2011/020604
Int. publication Feb. 24, 2011
Int. filing country WO
Int. filing PCT/EP2010/005071
Filed internationally Aug. 18, 2010
National stage date Apr. 19, 2012
National classification 424/192.1
Total number of claims 15
Exemplary claims 1
Number of drawings 6
Number of figures 6
Quick navigation
More similar inventions

N-Alkoxyamide Conjugates as Imaging Agents (US08852553, Oct. 7, 2014 / 13/723,333, Dec. 21, 2012, In an organic compound), Simon P. Robinson et al. / Lantheus Medical Imaging, Inc. (North Billerica, US)

Chimpanzee Adenovirus Vaccine Carriers (US08673319, March 18, 2014 / 13/529,518, June 21, 2012, Adenoviridae, adeno-like virus, or Parvoviridae), Annalisa Meola et al. / MSD Italia SRL (Rome, IT)

Natural Extract From Whole Banana Fruit ( Musa Spp) (US08496977, July 30, 2013 / 13/389,998, Aug. 11, 2010, Plant Material or Plant Extract of Undetermined Constitution as Active Ingredient), Munisekhar Medasani

Also viewed with this patent

Flow and Volume Regulated Inhalation for Treatment of Severe Oral Corticosteroid-Dependent Asthma (US08834848, Sept. 16, 2014 / 13/605,451, Sept. 6, 2012, Effervescent or Pressurized Fluid Containing), Philipp Kroneberg et al. / Activaero GmbH Research & Development (Gauting, DE)

Method of Treating Neuronal Injury by Administering Magnesium Chloride and PEG (US08840933, Sept. 23, 2014 / 11/418,153, May 3, 2006, Magnesium chloride), Jeffrey C Marx et al. / Warsaw Orthopedic, Inc. (Warsaw, US)

Pharmaceutical Compositions for Dehydrating, Atrophying and Eliminating Pathological Tissues (US08840931, Sept. 23, 2014 / 13/273,886, Oct. 14, 2011, Ferric), Hio man Tam et al.

New documents
  • Process for the Production of the Actinobacillus Pleuropneumoniae Toxins APXI or APXIII in a Liquid Culture Medium Under Supply of Air Enriched in Carbon Dioxide
  • Method for Manufacturing Nonvolatile Memory Device
  • Supply Chain Demand Satisfaction
  • Supply-Line Management Device
  • Storage Control Device and Method for Managing Snapshot